Study guide

7.2 Informed Consent Information and Meaningful Choice

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

7.2 Informed Consent Information and Meaningful Choice

Key Takeaways Explain This Topic AI

Consent is an ongoing understandable, voluntary process rather than a signature alone.

E6(R3) consent information includes withdrawal follow-up and handling of data after discontinuation.

Participants need adequate opportunity to ask questions and consider participation.

Last updated: October 2026

Informed Consent Information and Meaningful Choice

Note

Informed consent is the cornerstone of clinical research ethics. It represents an ongoing dialogue between the research team and the prospective participant—not a static, transactional signature on a piece of paper. For the CRA, verifying that informed consent was properly obtained and documented is the single most critical compliance task at every monitoring visit.

Under US FDA rules (21 CFR 50.20), no investigator may involve a human being as a subject in research unless the investigator has obtained the legally effective informed consent of the subject or the subject's legally authorized representative (the ICH E6(R3) term is legally acceptable representative, LAR). This protection operationalizes the Belmont principle of Respect for Persons by ensuring individual autonomy, comprehensive disclosure, full comprehension, and complete voluntariness.

The Concept of Informed Consent: Process vs. Document

A common error among novice clinical researchers is treating informed consent as a bureaucratic form to be collected before enrolling a subject. Regulatory authorities and GCP guidelines emphasize that informed consent is an ongoing communicative process :

Voluntariness: Participation must be entirely voluntary. The prospective participant must be free from any coercion, intimidation, or undue influence from clinicians, family members, or investigators.

Adequate Time to Consider: Under ICH E6(R3), prior to obtaining consent, the investigator (or designee) must give the subject ample time and opportunity to inquire about details of the trial and to decide whether or not to participate. Assess whether the person actually had adequate information, time and opportunity for questions; a scheduled appointment alone does not establish either adequate or inadequate consent.

Comprehension and Language: Information must be presented in clear, non-technical language understandable to the subject (adapted to the intended participant population). Technical medical jargon (e.g., "randomized double-blind crossover," "myelosuppression," "pharmacokinetics") must be explained in plain, accessible language.

Opportunity for Inquiry: All questions asked by the prospective subject or their family must be answered thoroughly to their complete satisfaction.

Receipt of Documented Copy: Under ICH E6(R3), prior to participation, the subject or LAR must receive a copy of the signed and dated written informed consent form and any other written information provided to the subjects.

Information supporting an informed decision

E6(R3) Annex 1 section 2.8.10 lists information to explain as applicable. Use the current approved materials rather than an R2-era 20-item mnemonic. The discussion covers purpose and experimental aspects; treatment and assignment probability; procedures and responsibilities; foreseeable risks and expected benefits; alternatives; injury treatment/compensation; payments and expenses; voluntariness; and contacts.

It also addresses follow-up after stopping treatment or withdrawing , how data will be handled at discontinuation, confidential direct access to source records, timely new information, reasons participation might end, expected duration and approximate number of participants. Trial results and actual treatment information should be made available when appropriate and when available from the sponsor, respecting whether the participant wants that information.

An information sheet can be complete yet poorly understood. Explain random assignment in ordinary language, distinguish research from individualised care, and avoid promising benefit. Ask the person to describe the main commitments in their own words. A signed form supports documentation; it does not substitute for a voluntary, informed conversation.

Detailed Analysis of Critical Elements

Statement of Research: Participants often experience the "therapeutic misconception"—falsely believing that every aspect of the research is tailored specifically to provide optimal individualized medical care. The ICF must explicitly clarify that the trial involves experimental research.

Treatment Assignment and Randomization: The participant must understand the concept of randomization, blinding, and the probability of receiving an active investigational drug versus an active comparator or placebo.

Foreseeable Risks and Inconveniences: Risks must detail known side effects, their potential severity, reversibility, and likelihood, as well as risks to an embryo, fetus, or nursing infant (including requirements for contraception).

Confidential Direct Access to Records: Under ICH E6(R3), the subject must be explicitly informed that monitor(s), auditor(s), regulatory authorities and, where applicable under requirements, the IRB/IEC may have authorised direct access to the subject's original medical records for verification of clinical trial data, without violating confidentiality.

Voluntary Withdrawal Without Loss of Benefits: The subject must be informed that refusal to participate or a decision to withdraw at any stage will involve no penalty or loss of benefits to which the subject is otherwise entitled in their routine medical care.

Compensation and Treatment for Trial-Related Injury: The document must clearly explain whether free medical treatment, hospitalization, or financial compensation is provided if the subject suffers an injury directly caused by the investigational product or study procedures.

Special Consenting Scenarios and Regulatory Safeguards

Clinical trials frequently encounter prospective participants who face linguistic, cognitive, or physical barriers to standard written consent:

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , WMA Declaration of Helsinki, 2024 , ICH E11(R1) .